Autolus Therapeutics (AUTL) Osake Kurssi

Autolus Therapeutics PLC is primarily active in the biotechnology and healthcare industries. As a leading biopharmaceutical company, Autolus Therapeutics focuses on developing and commercializing innovative treatments in the field of immunotherapy. Specializing in the development of next-generation T cell therapies, Autolus Therapeutics aims to revolutionize cancer treatment by harnessing the power of the patient's immune system. With a commitment to advancing breakthrough therapies and improving patient outcomes, Autolus Therapeutics PLC plays a pivotal role in the biotechnology and healthcare sectors.

The main competitors of Autolus Therapeutics PLC in the market include other companies specializing in cell and gene therapy, such as bluebird bio, CRISPR Therapeutics, and Juno Therapeutics. These companies also focus on developing innovative treatments for cancer and other serious diseases by utilizing similar technologies. Autolus Therapeutics PLC competes in the market by leveraging its unique platforms and therapeutic approaches to bring next-generation cell therapies.

Autolus Therapeutics PLC is a renowned biopharmaceutical company with a strong focus on developing innovative treatments for cancer patients. Founded in 2014, Autolus Therapeutics PLC has been at the forefront of advancing T-cell therapies to revolutionize cancer treatment. The company specializes in the development of next-generation, programmed T-cell therapies using its proprietary advanced cell programming technology. With a team of experts and collaborations worldwide, Autolus Therapeutics PLC is committed to delivering safe, effective, and individualized therapies to improve patient outcomes. Autolus Therapeutics PLC has achieved significant milestones and continues to make groundbreaking advancements in the field of oncology.

Autolus Therapeutics PLC, a leading clinical-stage biopharmaceutical company, has achieved several significant milestones. The company has successfully advanced its autologous CAR-T cell therapies for the treatment of cancer. Notably, Autolus Therapeutics received Investigational New Drug (IND) approvals from regulatory authorities, allowing them to initiate multiple clinical trials for their innovative therapies. Furthermore, the company has achieved positive clinical data and demonstrated encouraging results in patients with various types of cancer. Autolus Therapeutics' relentless dedication to advancing these therapies underscores their commitment to revolutionizing cancer treatment and improving patient outcomes.

Autolus Therapeutics PLC is primarily present in multiple countries and regions across the globe. The company operates in the United States, where it has its headquarters and a significant presence. Autolus Therapeutics also has a strong presence in the United Kingdom, as it originated from the University of London. Additionally, Autolus Therapeutics has expanded its reach to other European countries such as Germany, France, and Switzerland. The company's commitment to delivering innovative cell therapies has allowed it to establish a global footprint, continuously exploring opportunities to expand its presence in different regions worldwide.

Autolus Therapeutics PLC represents a commitment to advancing the field of cell therapy and transforming the lives of patients with cancer. The company's corporate philosophy is centered around innovation, collaboration, and patient-centricity. Autolus Therapeutics PLC strives to develop and commercialize next-generation, precision-engineered T cell therapies to treat hematological malignancies and solid tumors. Their dedication to scientific excellence, cutting-edge research, and strategic partnerships enables them to create novel therapies with the potential to revolutionize cancer treatment. Through their unwavering focus on improving patient outcomes, Autolus Therapeutics PLC is shaping the future of cancer care.

16 analyytikkoa arvioi tällä hetkellä Autolus Therapeutics-osaketta: 15 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Autolus Therapeutics-yhtiöltä 149,40 M USD liikevaihtoa ja −0,78 USD osakekohtaista tulosta.

Autolus Therapeutics Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Autolus Therapeutics-osake noteerataan hintaan 1,27 EUR (1,42 USD).

Autolus Therapeutics-osake (AUTL) on listattuna 4 pörssissä, muun muassa: NASDAQ (AUTL), Frankfurt (6A3A.F), München (6A3A.MU), Düsseldorf (6A3A.DU).

Autolus Therapeutics PLC is a company specializing in the development of CAR-T cell therapies. Their mission is to combat life-threatening diseases with innovative therapies and improve patients' quality of life. The business model of Autolus is divided into several areas. The first area is the research and development of new therapies. Autolus is able to develop new therapies through extensive clinical studies and research findings. They use state-of-the-art technologies and methods to explore the potential of CAR-T cell therapies. Another important element of Autolus' business model is production and commercialization. The company produces the therapies in their own facilities and works closely with other companies to bring their products to market. Their therapies are approved by regulatory authorities worldwide and used by doctors to treat patients. Another branch of the business is collaboration with other companies. Autolus works closely with other research organizations and pharmaceutical companies to develop new therapies. The exchange of knowledge and technology is of great importance in this regard. Autolus also offers products based on CAR-T technology. These products are an important part of their business model and contribute to their success. The products range from new cancer therapies to specific treatments for certain hematological disorders. The company holds several patents on therapies that could disrupt the therapy market. Autolus also aims for a global presence and plans to sell its products worldwide. Autolus' business model is based on a strong internal research department capable of developing innovative CAR-T cell therapies. The company works closely with other pharmaceutical companies to bring its therapies to market. A key aspect of the business model is the continuous research and development of new therapies to harness the potential of CAR-T cell technology. Overall, the business model of Autolus Therapeutics PLC is focused on the production of innovative technology and improving the treatment of life-threatening diseases. The company has a strong presence in the therapy market and aims to strengthen and expand its position.

odotettu liikevaihto Autolus Therapeutics on 149,40 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Autolus Therapeutics on −208,48 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Autolus Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −1,81. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Autolus Therapeutics-osakkeen arvostusta.

Autolus Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,53. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Autolus Therapeutics-osakkeen arvostuskennuslukuna.

Autolus Therapeutics:n Eulpool-laatuscore on 7/10.

Autolus Therapeutics:n ISIN on US05280R1005. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Autolus Therapeutics:n WKN on A2JNZJ. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Autolus Therapeutics:n ticker on AUTL. Tämä pörssinoteeraus käytetään Autolus Therapeutics-osakkeiden kauppaan pörssissä.